AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in line with the consensus of $15.49 billion.

The adjusted earnings were $2.12 per share, beating the consensus of $2.09.

AstraZeneca’s cancer business accounted for 45% of total sales. It increased 11% (+9% cc) to $7.03 billion.

Tagrisso sales were up 12% to $1.90 billion (+10% cc), Imfinzi revenues were up 39% (+37% cc) to $1.75 billion, Calquence sales increased 20% (+17% cc) to $967 million, and Lynparza sales increased 4% (+1% cc) to $878 million.

Cardiovascular, renal, and metabolism (CVRM) sales accounted for 20% of total sales, which fell 3% (-6% cc) to $3.05 billion.

The largest-selling drug in the segment, Farxiga, was up 7% (+2% cc) to $2.06 billion.

Respiratory & Immunology (R&I) sales increased 12% (+10 cc) to $2.37 billion. Symbicort revenues increased 3% (+2% cc) to $704 million, and Fasenra sales increased 12% (+10% cc) to $530 million.

Rare Disease drug sales were flat (-1% cc) at $2.37 billion. Ultomiris sales were up 16% (15% cc) to $1.27 billion, offset by a 26% decline in Soliris to $401 million.

U.S. sales jumped 6% to $6.93 billion for the quarter, whereas revenues from China rose 1% to $1.38 billion.

Pascal Soriot, CEO, commented on Tuesday, “The momentum across our company is continuing in 2026, and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing, including a substantial and growing number of trials of our transformative technologies, which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.”

Outlook

For fiscal year 2026, AstraZeneca expects total revenue to increase by a mid-to-high single-digit percentage, and core EPS is expected to increase by a low double-digit percentage.

AZN Price Action: AstraZeneca shares were up 2.82% at $193.31 at the time of publication on Tuesday. The stock is trading near its 52-week high of $193.97, according to Benzinga Pro data.

Photo by Robert Way via Shutterstock